November 2009 
Volume 39  Number 11
Pages 14 - 14
  PDF Version Available!


A report published in the British Medical Journal indicates that heart failure and mortality risks are lower in patients taking pioglitazone than in those taking rosiglitazone. Data were collected on 39,736 patients age 66 or older with type 2 diabetes who were started on rosiglitazone or pioglitazone. During a 72-month period, the risks of death and heart failure for those taking pioglitazone were 14% and 23% lower, respectively, than with rosiglitazone.

Because rosiglitazone has no clear clinical advantage over pioglitazone, continuing to prescribe it may not be worth the risks.

Source: de Vries CS, Russell-Jones DL. Rosiglitazone or pioglitazone in type 2 diabetes? BMJ . 2009;339:b3076.

PAIN MEDICATIONS Ibuprofen best for arm fractures in kids

Studying the effects of ibuprofen on postfracture pain in children, ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member